Telix Pharmaceuticals (NASDAQ:TLX) executives highlighted commercial momentum in prostate cancer imaging and outlined multiple clinical programs in oncology during an H.C. Wainwright discussion ...

Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical trials. A team at Heriot-Watt University, Edinburgh, leading the clinical ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

A new imaging technique developed at Memorial Sloan Kettering Cancer Center (MSK) shows promise for detecting deadly forms of lung cancer and prostate cancer. The technology uses a radioactive ...

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Researchers presented clinical study results on the dual-tracer PET imaging technique at the European urology conference with peer-reviewed publication forthcoming.

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...